-

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:

  • 25th Annual Needham Virtual Healthcare Conference
  • Definium Therapeutics Investor & Analyst Day
    • Date and Time: Wednesday, April 22, 2026 from 10:00 AM – 12:00 PM EDT (followed by lunch)
    • Location: Well& by Durst, 151 W 42nd St, New York, NY 10036
    • Registration Link (in person and virtual*): Definium Therapeutics Investor & Analyst Day
      *In-person attendance is limited to invited research analysts and institutional investors.
  • Needham Virtual Psychedelics Forum
    • Panel: Clinical Risk, Regulatory Reality and the Path to Scale
    • Date and Time: Monday, April 27, 2026 at 11:00 AM EDT
      Please contact your Needham representative for access to the panel presentation.
  • 2026 RBC Capital Markets Global Healthcare Conference

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

Industry:

Definium Therapeutics, Inc.

NASDAQ:DFTX
Release Versions
English

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

More News From Definium Therapeutics, Inc.

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today highlighted the advancement of its DT120 ODT (lysergide tartrate) clinical program and commercial strategy in major depressive disorder (MDD) and generalized anxiety disorder (GAD), with three anticipated topline re...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 70,860 common shares of the Company (the "Options") with effective grant dates of April 6, 2026...

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...
Back to Newsroom